Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
- Adedokun, Omoniyi J
- Xu, Zhenhua
- Marano, Colleen W
- Strauss, Richard
- Zhang, Hongyan
- Johanns, Jewel
- Zhou, Honghui
- Davis, Hugh M
- Reinisch, Walter
- Feagan, Brian G
- Rutgeerts, Paul
- Sandborn, William J
Publication date
January 2017
DOI Publisher
Elsevier Science BV Journal
issn:1873-9946Abstract
To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-severe ulcerative colitis [UC] from the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment [PURSUIT] studies.status: publishe
Add to ORKG